Solventum Corporation (NYSE:SOLV) Receives Consensus Recommendation of “Hold” from Brokerages

Solventum Corporation (NYSE:SOLV) has received a consensus recommendation of “Hold” from the thirteen research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $87.00.

A number of equities analysts have issued reports on the stock. Zacks Research cut shares of Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. Jefferies Financial Group assumed coverage on Solventum in a research note on Thursday, September 11th. They issued a “hold” rating and a $80.00 target price on the stock. Wells Fargo & Company upped their price target on Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research report on Monday, September 15th. UBS Group reiterated a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Finally, Wall Street Zen upgraded Solventum from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th.

Solventum Trading Down 0.5%

Shares of SOLV stock opened at $80.18 on Friday. The business has a 50-day moving average of $77.56 and a 200 day moving average of $74.83. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. Solventum has a 1-year low of $60.70 and a 1-year high of $88.20. The stock has a market capitalization of $13.91 billion, a PE ratio of 9.24, a P/E/G ratio of 8.46 and a beta of 0.26.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. The business had revenue of $2.10 billion for the quarter, compared to analysts’ expectations of $2.05 billion. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The business’s quarterly revenue was up .7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.64 EPS. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. As a group, sell-side analysts anticipate that Solventum will post 6.58 earnings per share for the current year.

Solventum announced that its board has authorized a stock repurchase plan on Thursday, November 20th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 7.5% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Institutional Investors Weigh In On Solventum

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Solventum by 5.3% during the third quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock valued at $1,249,847,000 after buying an additional 867,837 shares during the period. Independent Franchise Partners LLP grew its holdings in shares of Solventum by 27.2% during the 3rd quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock worth $941,645,000 after acquiring an additional 2,758,174 shares during the period. State Street Corp raised its position in shares of Solventum by 1.8% in the 3rd quarter. State Street Corp now owns 6,220,271 shares of the company’s stock worth $454,080,000 after acquiring an additional 112,261 shares in the last quarter. Davis Selected Advisers lifted its stake in shares of Solventum by 3.9% in the 2nd quarter. Davis Selected Advisers now owns 5,492,661 shares of the company’s stock valued at $416,563,000 after purchasing an additional 204,523 shares during the period. Finally, Boston Partners lifted its stake in shares of Solventum by 26.1% in the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after purchasing an additional 959,543 shares during the period.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.